Pull to refresh
Logo
What Changed
Following Why Sign Up
Talazoparib trial moves a targeted prostate cancer drug to an earlier stage

Talazoparib trial moves a targeted prostate cancer drug to an earlier stage

New Capabilities

The FDA cleared the Talzenna-Xtandi pair on October 26 for men with DNA-repair mutations, moving the combination one stage earlier

October 26th, 2026: FDA approves the combination for earlier-stage prostate cancer

Overview

Updated Oct 29

The Food and Drug Administration approved talazoparib (Talzenna) plus enzalutamide (Xtandi) on October 26 for men whose metastatic prostate cancer carries mutations in DNA-repair genes and who have not yet started hormone therapy for castration-resistant disease. The clearance moves the pair into the earlier castration-sensitive stage, where the trial showed it cut the risk of the cancer spreading or the patient dying by 52%.

In the 599-patient TALAPRO-3 trial, 77% of men on the combination had not progressed three years later, versus 56% on enzalutamide alone. The label covers the 12 genes on Pfizer's companion test, not just BRCA. Anemia is the main side effect: 51% of patients on the combination had severe anemia.

Why it matters

For the roughly one in four advanced prostate cancer patients with these DNA-repair mutations, adding one pill more than halved the risk of the cancer spreading.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

52%
Lower risk of progression or death
Adding talazoparib cut the risk of the cancer growing or the patient dying, versus enzalutamide alone (hazard ratio 0.48).
599
Patients enrolled
Men with metastatic castration-sensitive prostate cancer carrying HRR gene mutations.
77%
Progression-free at three years
Share of men on the combination whose cancer had not spread after three years, versus 56% on enzalutamide alone.
51%
Severe anemia
Grade 3 or higher anemia in the talazoparib group, versus 3% in the control group.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Neeraj Agarwal
Neeraj Agarwal
Global lead investigator, TALAPRO-3
Presented the final results at ASCO 2026
 Andrew Armstrong
Andrew Armstrong
Prostate cancer researcher and trial commentator
Public discussant of the TALAPRO-3 data

Organizations Involved

Pfizer Inc.
Pfizer Inc.
Global pharmaceutical company
Won FDA approval on October 26, 2026 for use in earlier-stage, HRR-mutated prostate cancer

Pfizer sells talazoparib (Talzenna) and co-markets enzalutamide (Xtandi), and is seeking to expand the pair into earlier prostate cancer.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Approved the combination on October 26, 2026 for HRR-mutated castration-sensitive prostate cancer

The FDA approved talazoparib plus enzalutamide for earlier-stage, HRR-mutated prostate cancer and authorized two FoundationOne tests to pick out eligible patients.

Timeline

June 2023 October 2026

5 events Latest: October 26th, 2026 · 2 weeks ago
Tap a bar to jump to that date

  1. FDA approves the combination for earlier-stage prostate cancer

    Latest Regulatory

    The FDA clears talazoparib plus enzalutamide for adults with HRR-mutated metastatic castration-sensitive prostate cancer, and authorizes two FoundationOne tests to identify eligible patients.

  2. FDA grants priority review

    Regulatory

    The FDA accepts Pfizer's application to expand the combination into castration-sensitive disease and sets a decision date in late 2026.

  3. TALAPRO-3 results unveiled at ASCO

    Clinical Data

    Investigators report a 52% reduction in the risk of progression or death, with benefit in both BRCA and non-BRCA patients. Data were released alongside a journal publication.

  4. TALAPRO-3 results published in the New England Journal of Medicine

    Publication

    Pfizer says the trial results were presented at the 2026 ASCO meeting and published in the New England Journal of Medicine at the same time.

  5. Combination approved for later-stage prostate cancer

    Regulatory

    The FDA clears talazoparib plus enzalutamide for HRR-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial.

Scenarios

1

FDA approves the combination for earlier-stage prostate cancer

Likely Resolves by Q1 2027

Discussed by: Pfizer; oncology trade press including Urology Times and CancerNetwork

The FDA clears talazoparib plus enzalutamide for HRR-mutated castration-sensitive prostate cancer on or near its late-2026 target date. Priority review status and a strong progression benefit point this way, though the agency could still narrow the label. Approval would let oncologists start the drug one stage earlier, when the cancer is more treatable.

2

FDA narrows the approval to BRCA-mutated patients only

Possible Resolves by Q1 2027

Discussed by: Oncology analysts noting the agency's earlier PARP inhibitor decisions

The FDA approves the combination but limits it to men with BRCA mutations, a subset of the broader HRR group. The trial showed a stronger effect in BRCA patients (hazard ratio 0.37) than non-BRCA patients (0.57), and the agency has restricted rival PARP combinations this way before. A narrow label would shrink the eligible population.

3

Mature data show men live longer, not just progress slower

Uncertain Resolves by End of 2028

Discussed by: Andrew Armstrong and other trial commentators tracking overall survival

Follow-up confirms a statistically significant overall survival benefit, the endpoint that matters most to patients. Early data trended in the drug's favor, with fewer deaths in the treatment group, but the survival analysis was not yet mature at publication. A confirmed benefit would settle the central open question about the combination.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2020

First PARP inhibitor approved in prostate cancer (2020)

The FDA approved olaparib for men with HRR-mutated metastatic castration-resistant prostate cancer, based on the PROfound trial. It was the first time a PARP inhibitor, a drug class born in ovarian and breast cancer, reached prostate cancer patients.

Then

Genetic testing for BRCA and related mutations became routine in advanced prostate cancer.

Now

It opened the door to PARP inhibitor combinations that later moved the class earlier in treatment.

Why this matters now

TALAPRO-3 continues that push, testing whether the same biology helps men at an earlier, hormone-sensitive stage.

2023

PARP-plus-hormone combinations reach castration-resistant disease (2023)

The FDA approved three PARP inhibitor and hormone-therapy combinations for castration-resistant prostate cancer, including talazoparib with enzalutamide. But it restricted some of them to BRCA-mutated patients rather than the full HRR group.

Then

Oncologists gained new options but had to match each drug to a specific mutation profile.

Now

The BRCA-versus-HRR labeling debate became the central regulatory question for the class.

Why this matters now

It shows why a TALAPRO-3 approval could still come with a narrower label than the trial population.

September 1998

Trastuzumab and the biomarker-drug model (1998)

The FDA approved trastuzumab for breast cancers that overexpress the HER2 protein, paired with a companion test. It tied a drug's use to a specific genetic feature of the tumor for the first time at scale.

Then

HER2 testing became standard, sorting patients into those likely to benefit and those unlikely to.

Now

It set the template for precision oncology: test first, then treat the matched subgroup.

Why this matters now

TALAPRO-3 follows that model, giving the drug only to men whose tumors carry the targeted DNA-repair mutations.

Sources

(10)
+4
Pfizer Urology Times CancerNetwork U.S. Food and Drug Administration The ASCO Post Fierce Pharma ASCO Daily News Oncology Central Pfizer Pfizer